|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu
L and He J: Report of incidence and mortality in China cancer
registries, 2009. Chin J Cancer Res. 25:10–21. 2013.PubMed/NCBI
|
|
3
|
Katanoda K, Hori M, Matsuda T, Shibata A,
Nishino Y, Hattori M, Soda M, Ioka A, Sobue T and Nishimoto H: An
updated report on the trends in cancer incidence and mortality in
Japan, 1958–2013. Jpn J Clin Oncol. 45:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Venook AP, Weiser MR and Tepper JE:
Colorectal cancer: All hands on deck. Am Soc Clin Oncol Educ Book
83–89. 2014. View Article : Google Scholar
|
|
5
|
Carrato A: Adjuvant treatment of
colorectal cancer. Gastrointest Cancer Res. 2 4 Suppl:S42–S46.
2008.PubMed/NCBI
|
|
6
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: A multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu T, Li Z, Gao CY and Cho CH: Mechanisms
of drug resistance in colon cancer and its therapeutic strategies.
World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin L, Yee SW, Kim RB and Giacomini KM:
SLC transporters as therapeutic targets: Emerging opportunities.
Nat Rev Drug Discov. 14:543–560. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dean M, Rzhetsky A and Allikmets R: The
human ATP-binding cassette (ABC) transporter superfamily. Genome
Res. 11:1156–1166. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szakács G, Annereau JP, Lababidi S,
Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD,
Reimers M, et al: Predicting drug sensitivity and resistance:
Profiling ABC transporter genes in cancer cells. Cancer Cell.
6:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Higgins CF: Multiple molecular mechanisms
for multidrug resistance transporters. Nature. 446:749–757. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shukla S, Chen ZS and Ambudkar SV:
Tyrosine kinase inhibitors as modulators of ABC
transporter-mediated drug resistance. Drug Resist Updat. 15:70–80.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lopez-Lopez E, Ballesteros J, Piñan MA, de
Toledo J Sanchez, de Andoin N Garcia, Garcia-Miguel P, Navajas A
and Garcia-Orad A: Polymorphisms in the methotrexate transport
pathway: A new tool for MTX plasma level prediction in pediatric
acute lymphoblastic leukemia. Pharmacogenet Genomics. 23:53–61.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou JY and Mansfield BC: The SLC37 family
of sugar-phosphate/phosphate exchangers. Curr Top Membr.
73:357–382. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen JQ and Russo J: Dysregulation of
glucose transport, glycolysis, TCA cycle and glutaminolysis by
oncogenes and tumor suppressors in cancer cells. Biochim Biophys
Acta. 1826:370–384. 2012.PubMed/NCBI
|
|
22
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
international union against cancer and the American joint Committee
on cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobin LH, Gospodarowicz M and Wittekind
Ch: International Union Against Cancer TNM Classification of
Malignant Tumors. 7th. Wiley-Blackwell; Oxford, UK: 2009
|
|
24
|
Okano M, Kumamoto K, Saito M, Onozawa H,
Saito K, Abe N, Ohtake T and Takenoshita S: Upregulated Annexin A1
promotes cellular invasion in triple-negative breast cancer. Oncol
Rep. 33:1064–1070. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koike T, Kimura N, Miyazaki K, Yabuta T,
Kumamoto K, Takenoshita S, Chen J, Kobayashi M, Hosokawa M,
Taniguchi A, et al: Hypoxia induces adhesion molecules on cancer
cells: A missing link between Warburg effect and induction of
selectin-ligand carbohydrates. Proc Natl Acad Sci USA. 101:pp.
8132–8137. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bartoloni L, Wattenhofer M, Kudoh J, Berry
A, Shibuya K, Kawasaki K, Wang J, Asakawa S, Talior I, Bonne-Tamir
B, et al: Cloning and characterization of a putative human glycerol
3-phosphate permease gene (SLC37A1 or G3PP) on 21q22.3: Mutation
analysis in two candidate phenotypes, DFNB10 and a glycerol kinase
deficiency. Genomics. 70:190–200. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bartoloni L and Antonarakis SE: The human
sugar-phosphate/phosphate exchanger family SLC37. Pflugers Arch.
447:780–783. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan CJ, Chen SY, Jun HS, Lin SR, Mansfield
BC and Chou JY: SLC37A1 and SLC37A2 are phosphate-linked,
glucose-6-phosphate antiporters. PLoS One. 6:e231572011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Iacopetta D, Lappano R, Cappello AR, Madeo
M, De Francesco EM, Santoro A, Curcio R, Capobianco L, Pezzi V,
Maggiolini M and Dolce V: SLC37A1 gene expression is up-regulated
by epidermal growth factor in breast cancer cells. Breast Cancer
Res Treat. 122:755–764. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cancer Genome Atlas N, . Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Siddiqui AD and Piperdi B: KRAS mutation
in colon cancer: A marker of resistance to EGFR-I therapy. Ann Surg
Oncol. 17:1168–1176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dietlein F, Kalb B, Jokic M, Noll EM,
Strong A, Tharun L, Ozretic L, Künstlinger H, Kambartel K,
Randerath WJ, et al: A Synergistic Interaction between Chk1- and
MK2 Inhibitors in KRAS-Mutant Cancer. Cell. 162:146–159. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu Z, Aref AR, Cohoon TJ, Barbie TU,
Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, et al:
Inhibition of KRAS-driven tumorigenicity by interruption of an
autocrine cytokine circuit. Cancer Discov. 4:452–465. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang JX, Liang Y and Gao W:
Clinicopathological and prognostic significance of sialyl Lewis X
overexpression in patients with cancer: A meta-analysis. Onco
Targets Ther. 9:3113–3125. 2016.PubMed/NCBI
|
|
36
|
Kumamoto K, Goto Y, Sekikawa K,
Takenoshita S, Ishida N, Kawakita M and Kannagi R: Increased
expression of UDP-galactose transporter messenger RNA in human
colon cancer tissues and its implication in synthesis of
Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants.
Cancer Res. 61:4620–4627. 2001.PubMed/NCBI
|
|
37
|
Takada A, Ohmori K, Yoneda T, Tsuyuoka K,
Hasegawa A, Kiso M and Kannagi R: Contribution of carbohydrate
antigens sialyl Lewis A and sialyl Lewis X to adhesion of human
cancer cells to vascular endothelium. Cancer Res. 53:354–361.
1993.PubMed/NCBI
|
